Tao Jiang

Prof. Tao Jiang


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
XJXin Jin
Xin Jin
TQTingting Qiu
Tingting Qiu
LLLi Li
Li Li
RYRilei Yu
Rilei Yu
XCXiguang Chen
Xiguang Chen
TJTao Jiang
Tao Jiang
The occurrence of obesity has increased across the whole world. Many epidemiological studies have indicated that obesity strongly contributes to the development of cancer, cardiovascular diseases, type 2 diabetes, liver diseases and other disorders, accounting for a heavy burden on the public and on health-care systems every year. Excess energy uptake induces adipocyte hypertrophy, hyperplasia and formation of visceral fat in other non-adipose tissues to evoke cardiovascular disease, liver diseases. Adipose tissue can also secrete adipokines and inflammatory cytokines to affect the local microenvironment, induce insulin resistance, hyperglycemia, and activate associated inflammatory signaling pathways. This further exacerbates the development and progression of obesity-associated diseases. Although some progress in the treatment of obesity has been achieved in preclinical and clinical studies, the progression and pathogenesis of obesity-induced diseases are complex and unclear. We still need to understand their links to better guide the treatment of obesity and associated diseases. In this review, we review the links between obesity and other diseases, with a view to improve the future management and treatment of obesity and its co-morbidities.

20 April 2015 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
JCJiachi Chiou
Jiachi Chiou
SWShengbiao Wan
Shengbiao Wan
KCKin-Fai Chan
Kin-Fai Chan
PSPui-Kin So
Pui-Kin So
DHDandan He
Dandan He
SCSheng Chen
Sheng Chen
We identified a potent NDM-1 inhibitor that formed a S–Se bond with the Cys 221 residue at the active site, thereby exhibiting a new inhibition mechanism with broad spectrum inhibitory potential.

1 July 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XJXin Jin
Xin Jin
RYRilei Yu
Rilei Yu
XWXuemin Wang
Xuemin Wang
CPChristopher G. Proud
Christopher G. Proud
TJTao Jiang
Tao Jiang

5 April 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ZYZongjiang Yu
Zongjiang Yu
WSWeizhi Sun
Weizhi Sun
WPWeibing Peng
Weibing Peng
Rilei YuRilei Yu
Rilei Yu
Guoqiang LiGuoqiang Li
Guoqiang Li
TJTao Jiang
Tao Jiang

6 January 2014 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JZJiuyang Zhao
Jiuyang Zhao
XLXiang Ling
Xiang Ling
SCShousong Cao
Shousong Cao
XLXiaojun Liu
Xiaojun Liu
SWShengbiao Wan
Shengbiao Wan
Fengzhi LiFengzhi Li
Fengzhi Li

Verified
Journal Article
Open access
PDF file
JZJiuyang Zhao
Jiuyang Zhao
WLWei Li
Wei Li
RMRui Ma
Rui Ma
SCShaopeng Chen
Shaopeng Chen
SRSumei Ren
Sumei Ren
TJTao Jiang
Tao Jiang
A series of novel potential DNA bis-intercalators were designed and synthesized, in which two glucuronic acids were linked by ethylenediamine, and the glucuronic acid was coupled with various chromophores, including quinoline, acridine, indole and purine, at the C-1 position. The preliminary binding properties of these compounds to calf thymus DNA (CT-DNA) have been investigated by UV-absorption and fluorescence spectroscopy. The results indicated that all the target compounds can interact with CT-DNA, and the acridine derivative, 3b, showed the highest key selection vector (KSV) value, which suggested that compound 3b binds most strongly to CT-DNA.